NCT03902548View on ClinicalTrials.gov

Initial Investigation of [18F]P16-129 in Alzheimer's Disease Patients and Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 21, 2018

Primary Completion Date

November 2, 2019

Study Completion Date

November 2, 2019

Conditions
Alzheimer Disease
Interventions
DRUG

[18F]P16-129

Injection of \< 10 mCi \[18F\]P16-129 followed by PET/CT scanning

Trial Locations (1)

21287

Johns Hopkins Medical Institutions, Baltimore

All Listed Sponsors
lead

Five Eleven Pharma, Inc.

INDUSTRY

NCT03902548 - Initial Investigation of [18F]P16-129 in Alzheimer's Disease Patients and Healthy Volunteers | Biotech Hunter | Biotech Hunter